Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYC-30937-EC extension in ulcerative colitis
NCT02764229Phase 2Terminated
- Sponsor
- Lycera
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of parimifasor in ulcerative colitis (UC), sponsored by Lycera. Primary endpoint: Number of Subjects With Types of Adverse Events (AEs), Serious Adverse Events and AEs That Led to Discontinuation of Treatment at 46 weeks. Started Nov 2016; status: terminated.
02
Drugs
parimifasor
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02764229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764229.